Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Indomethacin Effect on Elafibranor PK
NCT03985969Phase 1Completed
- Sponsor
- Genfit
- Start
- Sep 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elafibranor in Nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC), sponsored by Genfit. Primary endpoints: Area under curve from dosing time to infinity and Maximum plasma drug concentration. Started Sep 2019; status: completed.
02
Drugs
elafibranor
03
Conditions
Nonalcoholic steatohepatitis (NASH)primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT03985969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03985969.